Distalmotion has received FDA 510(k) clearance to expand the use of its Dexter surgical robot across additional gynecologic procedures, including sacrocolpopexy, sacrocervicopexy, sacrohysteropexy, and endometriosis resection.
The approval marks Dexter’s second gynecology clearance and expands its indications beyond existing gynecologic procedures, as well as general surgery applications such as hernia repair and gallbladder removal.
Related: SurGenTec gets FDA nod for lumbar facet fixation system
Dexter is designed as a compact, modular robotic system aimed at improving access to robotic surgery in hospitals, outpatient departments, and ambulatory surgical centers. The platform supports third-party surgical technologies and uses single-use wristed instruments designed for precision and reduced reprocessing needs.
Distalmotion CEO Greg Roche said:
“By enabling a comprehensive GYN service line, we are empowering care teams to maximize their workflows and deliver the combined benefits of robotics and same-day care to a broader patient population.”
The expanded clearance strengthens Distalmotion’s push to bring robotic-assisted surgery to more facilities, particularly in the growing outpatient surgery market.
